84 related articles for article (PubMed ID: 2416268)
1. A derivative of myelin-associated glycoprotein in cerebrospinal fluid of normal subjects and patients with neurological disease.
Yanagisawa K; Quarles RH; Johnson D; Brady RO; Whitaker JN
Ann Neurol; 1985 Oct; 18(4):464-9. PubMed ID: 2416268
[TBL] [Abstract][Full Text] [Related]
2. Myelin-associated glycoprotein in multiple sclerosis lesions: a quantitative and qualitative analysis.
Möller JR; Yanagisawa K; Brady RO; Tourtellotte WW; Quarles RH
Ann Neurol; 1987 Oct; 22(4):469-74. PubMed ID: 2449119
[TBL] [Abstract][Full Text] [Related]
3. [Determination of myelin basic protein in the cerebrospinal fluid in neurologic diseases].
Bürgisser P; Matthieu JM; de Tribolet N; Gautier E
Schweiz Med Wochenschr; 1982 May; 112(18):643-7. PubMed ID: 6177033
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of cerebrospinal fluid myelin basic protein in patients with neurological illness.
Davies L; McLeod JG; Muir A; Hensley WJ
Clin Exp Neurol; 1987; 24():5-10. PubMed ID: 2478320
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunoassay of myelin basic protein in spinal fluid. An index of active demyelination.
Cohen SR; Herndon RM; McKhann GM
N Engl J Med; 1976 Dec; 295(26):1455-7. PubMed ID: 995142
[TBL] [Abstract][Full Text] [Related]
6. Determination of a native proteolytic site in myelin-associated glycoprotein.
Stebbins JW; Jaffe H; Fales HM; Möller JR
Biochemistry; 1997 Feb; 36(8):2221-6. PubMed ID: 9047323
[TBL] [Abstract][Full Text] [Related]
7. Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders.
Whitaker JN; Lisak RP; Bashir RM; Fitch OH; Seyer JM; Krance R; Lawrence JA; Ch'ien LT; O'Sullivan P
Ann Neurol; 1980 Jan; 7(1):58-64. PubMed ID: 6153879
[TBL] [Abstract][Full Text] [Related]
8. Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia.
Nobile-Orazio E; Francomano E; Daverio R; Barbieri S; Marmiroli P; Manfredini E; Carpo M; Moggio M; Legname G; Baldini L
Ann Neurol; 1989 Oct; 26(4):543-50. PubMed ID: 2479332
[TBL] [Abstract][Full Text] [Related]
9. Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies.
Trojaborg W; Hays AP; van den Berg L; Younger DS; Latov N
Muscle Nerve; 1995 Jul; 18(7):730-5. PubMed ID: 7540258
[TBL] [Abstract][Full Text] [Related]
10. Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody.
Rech J; Hueber AJ; Kallert S; Leipe J; Kalden JR; Beck M; Schett G; Schulze-Koops H
Ther Apher Dial; 2008 Jun; 12(3):205-8. PubMed ID: 18503697
[TBL] [Abstract][Full Text] [Related]
11. Myelin-associated glycoprotein in demyelinating disorders.
Quarles RH
Crit Rev Neurobiol; 1989; 5(1):1-28. PubMed ID: 2475262
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
13. Detection of myelin basic protein in cerebrospinal fluid.
Ohta M; Ohta K
Expert Rev Mol Diagn; 2002 Nov; 2(6):627-33. PubMed ID: 12465458
[TBL] [Abstract][Full Text] [Related]
14. [Polyneuropathy with IgM-antibody to myelin-associated glycoprotein without detectable M-protein by conventional analysis--report of a case].
Kageyama Y; Ichikawa K; Fujioka A; Kanatsu K; Saito T
Rinsho Shinkeigaku; 1993 Feb; 33(2):210-2. PubMed ID: 7686455
[TBL] [Abstract][Full Text] [Related]
15. Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody.
Mendell JR; Sahenk Z; Whitaker JN; Trapp BD; Yates AJ; Griggs RC; Quarles RH
Ann Neurol; 1985 Mar; 17(3):243-54. PubMed ID: 2581496
[TBL] [Abstract][Full Text] [Related]
16. [Polyneuropathies and gammapathies: a form with antiglycoprotein MAG antibodies].
Steck AJ; Meier C; Vandevelde M; Regli F
Rev Neurol (Paris); 1984; 140(1):28-36. PubMed ID: 6198705
[TBL] [Abstract][Full Text] [Related]
17. Soluble myelin-associated glycoprotein released from damaged white matter inhibits axonal regeneration.
Tang S; Qiu J; Nikulina E; Filbin MT
Mol Cell Neurosci; 2001 Sep; 18(3):259-69. PubMed ID: 11591127
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to myelin-associated glycoprotein (MAG) in the cerebrospinal fluid of multiple sclerosis patients.
Möller JR; Johnson D; Brady RO; Tourtellotte WW; Quarles RH
J Neuroimmunol; 1989 Mar; 22(1):55-61. PubMed ID: 2465313
[TBL] [Abstract][Full Text] [Related]
19. Failure to detect anti-MAG antibodies by RIA in CSF of patients with multiple sclerosis.
Nobile-Orazio E; Spagnol G; Scarlato G
J Neuroimmunol; 1986 Apr; 11(2):165-9. PubMed ID: 2419358
[TBL] [Abstract][Full Text] [Related]
20. Soluble myelin-associated glycoprotein (MAG) found in vivo inhibits axonal regeneration.
Tang S; Woodhall RW; Shen YJ; deBellard ME; Saffell JL; Doherty P; Walsh FS; Filbin MT
Mol Cell Neurosci; 1997; 9(5-6):333-46. PubMed ID: 9361272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
